Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2022-11-22 00:00:00 ET · period of report 2022-11-18 · accession 0001787306-22-000077 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-22 | 2022-11-18 | ARQT | Matsuda Masaru | See Remark | A - Grant | $0.00 | +4,875 | 21.3K | +30% | $0 | |
| 2022-11-22 | 2022-11-21 | ARQT | Matsuda Masaru | See Remark | S - Sale | $18.19 | -1,720 | 19.5K | -8% | -$31.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-18 | A | A | 4,875 | $0.00 | 21,255 | D | — | — | (F1) Represents performance stock units ("PSUs") initially granted on January 3, 2022, that were subject to a performance-based vesting condition. The vesting condition was determined to be satisfied on November 18, 2022. The PSUs will vest fully on May 27, 2025, subject to the Reporting Person's continued service to the Issuer on such vesting date. (F2) Includes 13,300 Restricted Stock Units ("RSUs"). |
| 2 | Common | Common Stock | 2022-11-21 | S | D | 1,720 | $18.19 | 19,535 | D | — | — | (F2) Includes 13,300 Restricted Stock Units ("RSUs"). |